Researchers report that all nine patients who were successfully treated for ADA-SCID in a UCLA clinical trial from 2009 to 2012 are still disease-free.
The five-year award from California’s stem cell agency will help prepare young scientists and physicians to become leaders in the regenerative medicine field.
Research brief: A UCLA team has demonstrated that altering a key molecule used in the therapy yields superior and longer-lasting results in mouse models.